

NEWS RELEASE

FOR IMMEDIATE RELEASE

September 18, 2017

Methapharm Appointed Canadian Distributor for TEPADINA[®] (Thiotepa for injection, BP)

Methapharm is pleased to announce that Adienne SA has appointed Methapharm as the Canadian distributor for TEPADINA[®] (Thiotepa for injection, BP) in Canada.

TEPADINA is indicated in combination with other chemotherapeutic products as part of a high dose chemotherapy (HDCT) consolidation regimen followed by autologous stem cell transplantation (ASCT) for adult patients with central nervous system (CNS) lymphoma.* TEPADINA has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for TEPADINA please refer to Health Canada's Notice of Compliance with conditions-drug products web site: <http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php>

About Adienne SA

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal products, clinical and preclinical product candidates. ADIENNE is focused on orphan drug development for the treatment of various hematological and immunological diseases. In addition, the Group has its own GMP-approved manufacturing facility, which is authorized for the production of biotechnological sterile products for clinical trials and commercial use.

About Methapharm Inc.

Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of specialty products. The addition of TEPADINA is in keeping with Methapharm's mission to make specialty products available in the markets we serve.

For more information about Methapharm or business development inquiries, please contact:

Chris Calenti

Exec. Vice President

Tel: (+1) 519.751.3602 x7222

*Please consult the Canadian Product Monograph available on our website at www.methapharm.com for important information relating to adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling us at 1-800-287-7686 ext 7804.